J&J builds world’s largest sup­ply chain base

China Daily (Canada) - - ACROSSAMERICA - By LU HONGYAN and MA LIE in Xi’an

John­son & John­son, a For­tune 500 com­pany, is tak­ing a big step to meet grow­ing de­mand from China and other emerg­ing mar­kets by build­ing its largest sup­ply chain pro­duc­tion base in Xi’an, the cap­i­tal of Shaanxi prov­ince, at a cost of $300 mil­lion.

The base will be­come the top bio-phar­ma­ceu­ti­cal fac­tory with the largest floor area in China af­ter it is com­pleted and put into oper­a­tion in 2018.

The ground­break­ing cer­e­mony was held on Thurs­day in Xi’an High-tech De­vel­op­ment Zone. J&J an­nounced at the cer­e­mony that the pro­duc­tion ca­pac­ity of the newly built pro­duc­tion base will be much higher than its ex­ist­ing fac­to­ries.

Ac­cord­ing to Ce­sar Ro­driguez, pres­i­dent of Xi’an Janssen Phar­ma­ceu­ti­cal Ltd, a J&J sub­sidiary in China, the 267,000 square me­ters will be home to the in­no­va­tion cen­ter of J&J’s sup­ply chain in Asia to en­able it to bet­ter meet the grow­ing de­mands of the Chi­nese and people in other emerg­ing mar­kets.

“The ground­break­ing cer­e­mony for the new pro­duc­tion base is not only an im­por­tant mile­stone in the co­op­er­a­tion be­tween Xi’an Janssen and the high-tech de­vel­op­ment zone, but also of great sig­nif­i­cance to the pa­tients who need medicines in China and across the pan-Asian re­gion,” Ro­driguez said.

The new plant will fea­ture world-class man­u­fac­tur­ing tech­nol­ogy, ad­vanced qual­ity sys­tems and sig­nif­i­cantly greater ca­pac­ity than its cur­rent Xi’an-based fa­cil­i­ties. It will set a new stan­dard in phar­ma­ceu­ti­cal man­u­fac­tur­ing in China.

With fully au­to­mated op­er­a­tions and elec­tronic record­ing for safety and qual­ity, the plant is ex­pected to reach a full fu­ture ca­pac­ity of 4 bil­lion tablets and cap­sules and up to 57 mil­lion tubes of creams.

“The new pro­duc­tion base will con­tinue Xi’an Janssen’s 30 years of his­tory to pro­vide in­no­va­tive and qual­ity prod­ucts to the mar­ket and will make a great ef­fort with its top range pro­duc­tion ca­pac­ity to meet the rapidly grow­ing needs of pa­tients.

It will pro­mote the sus­tain­able de­vel­op­ment of China’s phar­ma­ceu­ti­cal in­dus­try,” Ro­driguez said. Xi’an Janssen, es­tab­lished in 1985, pro­duces medicines for men­tal and neu­ro­log­i­cal dis­or­ders as well as treat­ments for tu­mors, au­toim­mune, gas­troin­testi­nal and fun­gal dis­eases.

The com­pany has car­ried out more than 50 co­op­er­a­tion projects in the fields of medicine, pub­lic health, med­i­cal re­search and de­vel­op­ment and so­cial re­spon­si­bil­ity in the past 30 years.

The in­vest­ment agree­ment for the base was signed by J& J and of­fi­cials from Xi’an High­tech De­vel­op­ment Zone in Bei­jing on Feb 28.

The project is made up of three parts: the new sup­ply chain pro­duc­tion base, Asia’s largest pro­duc­tion base for vac­cines and an in­tro­duc­tion and reg­is­tra­tion cen­ter for for­eign bio­med­i­cal projects into China, said An Jianli, di­rec­tor of the ad­min­is­tra­tion com­mit­tee of Xi’an High-tech De­vel­op­ment Zone.

A to­tal of 340 bio­med­i­cal com­pa­nies have started pro­duc­tion in Xi’an. Con­tact the writ­ers at luhongyan@chi­nadaily.com.cn and malie@chi­nadaily.com.cn

Newspapers in English

Newspapers from China

© PressReader. All rights reserved.